Pramipexole, recommended for clinical use in early stages of PD, increases VMAT2 activity, increasing dopamine packaging and secretion in vesicles, reducing the cytosolic dopamine concentration, and thereby protecting dopaminergic neurons [44]. Here, SLC18A2 is linked to Parkinson disease.